Polypoidal choroidal vasculopathy versus neovascular age related macular degeneration: a comparison of demographics, clinical presentation, and treatment outcomes in Nigerians
{"title":"Polypoidal choroidal vasculopathy versus neovascular age related macular degeneration: a comparison of demographics, clinical presentation, and treatment outcomes in Nigerians","authors":"Ogugua Ndubuisi Okonkwo , Adekunle Olubola Hassan , Toyin Akanbi , Chineze Agweye , Arinze Anthony Onwuegbuna","doi":"10.1016/j.jfop.2024.100118","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>To compare the demographics, clinical presentation, and outcomes of intravitreal (IV) anti-VEGF monotherapy in the management of treatment-naïve polypoidal choroidal vasculopathy (PCV) and neovascular age-related macular degeneration (nAMD) in Nigerians.</p></div><div><h3>Methods</h3><p>This is a retrospective, interventional, comparative study. Data obtained from consecutively treated PCV and nAMD patients include age, sex, laterality, symptom duration, LogMAR visual acuity (pre- & post-treatment), occurrence of vitreous hemorrhage, optical coherence tomography central macular thickness (CMT), and duration of clinic visits. Data was analyzed using IBM SPSS version 22.0, P < 0.05.</p></div><div><h3>Results</h3><p>The sample population was 162 patients/191 eyes (nAMD 85 patients/106 eyes, and PCV 77 patients/85 eyes). The nAMD patients were older than the PCV patients (72.48 +/− 8.81 years versus 62.04 +/− 10.50 years) p = 0.000. Females constituted 45.9% of the nAMD and 57.1% of the PCV patients, p = 0.1. Symptom duration: nAMD 11 months and PCV 12 months. Bilaterality: nAMD > PCV (38% versus 19%) p = 0.036. Vitreous hemorrhage: more common in PCV (42% versus 19%) p = 0.001. nAMD patients had poorer baseline vision (LogMAR 1.4 versus LogMAR 1.2) p = 0.2, thicker maculae (361 microns versus 331 microns), and received more mean intravitreal anti-VEGF injections (4 versus 3). Visual and anatomical outcomes were better for PCV; final vision (LogMAR 0.89 versus LogMAR 1.04), p = 0.064, final CMT (247 microns versus 331 microns), p = 0.05. nAMD patients had higher rate of >12 months follow-up (57.6% versus 35.0%) p = 0.002.</p></div><div><h3>Conclusion</h3><p>Demographic and clinical differences exist between PCV and nAMD. Though chronic presentation for both diseases is common, treatment improves vision and anatomy in most patients, moreso in PCV. Earlier treatment will likely yield better outcomes.</p></div>","PeriodicalId":100740,"journal":{"name":"JFO Open Ophthalmology","volume":"7 ","pages":"Article 100118"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949889924000424/pdfft?md5=f3a720942c6fb6a8e9e735c22c44dc93&pid=1-s2.0-S2949889924000424-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JFO Open Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949889924000424","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose
To compare the demographics, clinical presentation, and outcomes of intravitreal (IV) anti-VEGF monotherapy in the management of treatment-naïve polypoidal choroidal vasculopathy (PCV) and neovascular age-related macular degeneration (nAMD) in Nigerians.
Methods
This is a retrospective, interventional, comparative study. Data obtained from consecutively treated PCV and nAMD patients include age, sex, laterality, symptom duration, LogMAR visual acuity (pre- & post-treatment), occurrence of vitreous hemorrhage, optical coherence tomography central macular thickness (CMT), and duration of clinic visits. Data was analyzed using IBM SPSS version 22.0, P < 0.05.
Results
The sample population was 162 patients/191 eyes (nAMD 85 patients/106 eyes, and PCV 77 patients/85 eyes). The nAMD patients were older than the PCV patients (72.48 +/− 8.81 years versus 62.04 +/− 10.50 years) p = 0.000. Females constituted 45.9% of the nAMD and 57.1% of the PCV patients, p = 0.1. Symptom duration: nAMD 11 months and PCV 12 months. Bilaterality: nAMD > PCV (38% versus 19%) p = 0.036. Vitreous hemorrhage: more common in PCV (42% versus 19%) p = 0.001. nAMD patients had poorer baseline vision (LogMAR 1.4 versus LogMAR 1.2) p = 0.2, thicker maculae (361 microns versus 331 microns), and received more mean intravitreal anti-VEGF injections (4 versus 3). Visual and anatomical outcomes were better for PCV; final vision (LogMAR 0.89 versus LogMAR 1.04), p = 0.064, final CMT (247 microns versus 331 microns), p = 0.05. nAMD patients had higher rate of >12 months follow-up (57.6% versus 35.0%) p = 0.002.
Conclusion
Demographic and clinical differences exist between PCV and nAMD. Though chronic presentation for both diseases is common, treatment improves vision and anatomy in most patients, moreso in PCV. Earlier treatment will likely yield better outcomes.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
